59272-27-4

Basic information

• Product Name: 2-(3-Trifluoromethylphenyl)amino-3-hydroxy-methylpyridine
• Synonyms: 2-(3-Trifluoromethylphenyl)amino-3-hydroxy-methylpyridine
• CAS NO: 59272-27-4
• Molecular Weight: 268.238
• Mol File: 59272-27-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-(3-Trifluoromethylphenyl)amino-3-hydroxy-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Trifluoromethylphenyl)amino-3-hydroxy-methylpyridine(59272-27-4)
• EPA Substance Registry System: 2-(3-Trifluoromethylphenyl)amino-3-hydroxy-methylpyridine(59272-27-4)

Safety Data

• Hazardous Substances Data: 59272-27-4(Hazardous Substances Data)

Upstream product

• 51703-19-6 ethyl 2-[3-(trifluoromethyl)phenylamino]pyridine-3-carboxylate 
• 22560-16-3 lithium triethylborohydride 
• 2942-59-8 2-chloronicotinic acid 
• 4394-00-7 Niflumic Acid 
• 98-16-8 3-trifluoromethylaniline 

Downstream Products

• 113168-84-6 2-(3-Cyanophenyl)aminonicotinaldehyde 
• 127555-40-2 1,3-dihydro-3-(phenylthio)-1-(3-trifluoromethylphenyl)-2H-pyrrolo[2,3-b]pyridin-2-one 
• 128271-40-9 (3-Phenylsulfanylmethyl-pyridin-2-yl)-(3-trifluoromethyl-phenyl)-amine 
• 127555-31-1 1,3-dihydro-3,3-dimethyl-1-[3-(trifluoromethyl)phenyl]-2H-pyrrolo[2,3-b]pyridin-2-one 
• 104902-32-1 2-(3-Trifluoromethylphenyl)amino-3-pyridinecarboxaldehyde 

Relevant articles and documents

Activation and inhibition of kidney CLC-K chloride channels by fenamates

CLC-K Cl- channels are selectively expressed in kidney and ear, where they are pivotal for salt homeostasis, and loss-offunction mutations of CLC-Kb produce Bartter's syndrome type III. The only ligand known for CLC-K channels is a derivative o

NAPHTHYRIDINE DERIVATIVES, THEIR METHODS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS IN WHICH THEY ARE PRESENT, USEFUL ESPECIALLY AS ANTIPROLIFERATIVE DRUGS

-

Substituted 1,3-Dihydro-2H-pyrrolopyridin-2-ones as Potential Antiinflammatory Agents

A series of analogues based on the 1,3-dihydro-2H-pyrrolopyridin-2-one ring system have been synthesized and shown to possess oral antiinflammatory activity in both the reverse passive Arthus reaction (RPAR) pleural cavity assay in rats and in the adjuvant-induced arthritic rat model (AAR).Several members of this series additionally exhibit an inhibitory effect on the in vivo production of prostaglandin- and leukotriene-derived products or arachidonic acid metabolism although these compounds exhibit no significant inhibitory activity against the cyclooxygenase and 5-lipoxygenase enzymes in vitro.Structure-activity relationships in this series are discussed.